Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q2 2022 · 10-Q
Revenue$674.00K$674.00K±0.0% vs Q2 2021 Net Income-$10.53M-$10.53MN/M vs Q2 2021 EPS Diluted$0.27$0.27+125.0% vs Q2 2021 Operating Income-$11,417,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,510,000N/M Margins · derivedOperating margin-1693.9%−1033.7 pt vs Q2 2021
Net margin-1562.8%−982.8 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 10, 2022 · 41 d after period end